CD274 and hepatocellular carcinoma: In addition, the FDA has also approved the combination of Atezolizumab, ICI against programmed cell death protein ligand -1 (PD-L1), and Bevacizumab as first-line treatment for HCC patients based on the response rates in the IMbrave150 trial 9.